In the study, experts evaluated blinatumomab (Blincyto) when added to chemotherapy vs chemotherapy alone for the treatment of ...

Neoadjuvant pembrolizumab with chemotherapy led to greater pathologic regression based on percent residual volume tumor vs ...

BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow ...

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses how novel endocrine ...

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer ...

Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses some of the emerging ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

Jacob E. Berchuck, MD, discusses the potential of liquid biopsies to enhance clinical decision-making regarding PSMA-directed therapies.

Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, ...

Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognosis.

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast ...